Company Profile
Novartis AG Stock Price, News & Analysis
- Ticker:
- NVS
- Exchange:
- NYSE
- Sector:
- Biopharma, Novel Therapies, Gene Therapy
- Location:
- Switzerland
Stock performance
154.21 USD (-0.15%)
Close
Last updated: August 6, 2026
274B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, NVS was little changed and closed at $154.21. No new same-company headline was identified in the current news window.
Company overview
Business overview
Novartis is a global medicines company with major exposure to innovative therapies across oncology, immunology, neuroscience, and cardiovascular disease. The company has been reshaping its portfolio around higher-growth, innovation-driven products.
Geographic Base and Sector Classification
Headquartered in Switzerland and listed on NYSE as an ADR, Novartis is a global biopharma with strong European and U.S. exposure. Its profile is defined by global commercial scale and a high-quality pipeline.
Business Model Characteristics
Novartis generates value through branded medicines, launches, and pipeline reinvestment. Investors follow earnings quality, launch cadence, and whether the company can continue replacing mature products with growth assets.
Position Within the Biotechnology Landscape
Novartis sits among the most important global pharma names because it combines scale with consistent innovation. It is less volatile than clinical-stage biotech, but pipeline and regulatory updates can still shift the story.
Future catalysts
Novartis should be tracked for Fabhalta expansion, remibrutinib progress, and any late-stage update that keeps the growth mix shifting away from older franchises. The key question is whether the update shows enough repeatable demand to look like a durable revenue driver rather than a one-quarter bump. If adoption broadens, sentiment can improve faster than the reported numbers alone would suggest.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Novartis AG (NVS)?
Novartis AG (NVS) most recently closed at 154.21 USD, a -0.15% move versus the previous session.
What is the market cap of Novartis AG (NVS)?
Novartis AG currently has a market capitalization of 274B USD on BioPharmSignal.
What does Novartis AG do?
Novartis is a global medicines company with major exposure to innovative therapies across oncology, immunology, neuroscience, and cardiovascular disease. The company has been reshaping its portfolio around higher-growth, innovation-driven products.
On which exchange is NVS stock listed?
Novartis AG (NVS) is associated with NYSE, Switzerland, Biopharma, Novel Therapies, Gene Therapy.
What is remibrutinib?
Novartis should be tracked for Fabhalta expansion, remibrutinib progress, and any late-stage update that keeps the growth mix shifting away from older franchises.
Which conditions is Novartis AG targeting with remibrutinib?
Novartis AG is associated with oncology, immunology, cardiovascular disease based on its company overview and current catalyst commentary.
How does Novartis AG describe recent progress with remibrutinib?
Novartis should be tracked for Fabhalta expansion, remibrutinib progress, and any late-stage update that keeps the growth mix shifting away from older franchises.
What is Novartis?
Novartis is a global medicines company with major exposure to innovative therapies across oncology, immunology, neuroscience, and cardiovascular disease.